Renuka P Limgala

List of Publications by Year
in descending order

17	452	933447 10	888059 17
papers	citations	h-index	g-index

18	18	18	652
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Pilot Study of Omalizumab in Eosinophilic Esophagitis. PLoS ONE, 2015, 10, e0113483.	2.5	114
2	Hepatitis C Virus Internal Ribosome Entry Site-mediated Translation Is Stimulated by Specific Interaction of Independent Regions of Human La Autoantigen. Journal of Biological Chemistry, 2003, 278, 12231-12240.	3.4	71
3	Efficient Procurement of Epithelial Stem Cells from Human Tissue Specimens Using a Rho-Associated Protein Kinase Inhibitor Y-27632. Tissue Engineering - Part A, 2010, 16, 1363-1368.	3.1	64
4	La Protein Binding at the GCAC Site Near the Initiator AUG Facilitates the Ribosomal Assembly on the Hepatitis C Virus RNA to Influence Internal Ribosome Entry Site-mediated Translation. Journal of Biological Chemistry, 2004, 279, 29879-29888.	3.4	48
5	Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. PLoS ONE, 2016, 11, e0168135.	2.5	25
6	Gaucheromas: When macrophages promote tumor formation and dissemination. Blood Cells, Molecules, and Diseases, 2018, 68, 100-105.	1.4	25
7	A Peptide Derived from RNA Recognition Motif 2 of Human La Protein Binds to Hepatitis C Virus Internal Ribosome Entry Site, Prevents Ribosomal Assembly, and Inhibits Internal Initiation of Translation. Journal of Virology, 2005, 79, 9842-9853.	3.4	21
8	Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site. Archives of Virology, 2006, 151, 509-524.	2.1	19
9	Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease. Blood Cells, Molecules, and Diseases, 2016, 59, 8-15.	1.4	19
10	Leader RNA of Rinderpest virus binds specifically with cellular La protein: a possible role in virus replication. Virus Research, 2004, 104, 101-109.	2.2	17
11	Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease. Biomolecules, 2020, 10, 526.	4.0	9
12	Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease. Blood Cells, Molecules, and Diseases, 2018, 68, 81-85.	1.4	5
13	Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants. JIMD Reports, 2021, 59, 60-68.	1.5	5
14	Pregnancy Outcomes in Late Onset Pompe Disease. Life, 2020, 10, 194.	2.4	4
15	Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta. American Journal of Translational Research (discontinued), 2019, 11, 1683-1696.	0.0	3
16	Diffuse Cutaneous Mastocytosis, Bullous Variant, Presenting in a Six-Month-Old Infant. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 341-342.	3.8	2
17	The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease. International Journal of Molecular Sciences, 2020, 21, 7213.	4.1	1